PharmaShots Weekly Snapshots (July 18 – 22, 2022)
Published: July 18, 2022 | Tags: InnoCare, Tafasitamab, Lenalidomide, Diffuse Large B-Cell Lymphoma, Approval, Regulatory
Published: July 18, 2022 | Tags: PharmaCyte, CypCaps, Cell-in-a-Box Technology, Locally Advanced Inoperable Pancreatic Cancer, US, FDA, Animal Health
Published: July 18, 2022 | Tags: Vertex, Verve Therapeutics, In Vivo Gene Editing Program, Liver Disease, Biotech
Sanofi Reports the Selection of IPH6401/SAR’514 in IND-Enabling Studies for Cancer
Published: July 18, 2022 | Tags: Sanofi, IPH6401, SAR’514, Cancer, IND-Enabling Studies, Clinical Trial, ANKET platform
Published: July 18, 2022 | Tags: Karyopharm, Menarini, Nexpovio, Selinexor, Multiple Myeloma, Regulatory, EC, Marketing Authorisation
Published: July 18, 2022 | Tags: Silverback Therapeutics, ARS, Neffy, Type I Allergic Reactions, Merger Agreement, Pharma
Published: July 17, 2022 | Tags: Takeda, Hyqvia, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Clinical Trial, P-III, ADVANCE-1 Trial
ITM Entered into a Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177 to Treat Solid Tumors
Published: July 17, 2022 | Tags: ITM, Y-mAbs, n.c.a. Lutetium-177, Solid Tumors, Pharma, GD2-SADA: 177Lu-DOTA complex
Eiger's Zokinvy (ionafarnib) Receives EC's Marketing Authorization for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Published: July 17, 2022 | Tags: Eiger, Zokinvy, ionafarnib, Hutchinson-Gilford Progeria Syndrome, Processing-Deficient Progeroid Laminopathies, Regulatory, EC, Marketing Authorization
Published: July 17, 2022 | Tags: LEO Pharma, Adbry, tralokinumab-ldrm, Atopic Dermatitis, Clinical Trial, P-III, ECZTRA 3 Trial
Published: July 17, 2022 | Tags: Alvotech, AVT03, Prolia, Xgeva, denosumab, Bone Disease, Biosimilar
Published: July 17, 2022 | Tags: F-Star, Takeda, Immuno-oncology Bispecific Antibody, Cancer, Biotech, Fcab Technology, mAb2 Platforms, Gamma Delta (γδ) T cell Engager
AbbVie Collaborated with iSTAR Medical to Develop and Commercialize MINIject Device for Glaucoma
Published: July 16, 2022 | Tags: AbbVie, IStar Medical, MINIject Device, Glaucoma, MedTech
Published: July 16, 2022 | Tags: Merck, Keytruda, pembrolizumab, Head, Neck Squamous Cell Carcinoma, Clinical Trial, P-III (KEYNOTE-412) Trial
Published: July 16, 2022 | Tags: Apellis, Pegcetacoplan, Geographic Atrophy, Regulatory, US, FDA, Priority Review
Gilead Signs New Joint Procurement Agreement with the EC to Supply Veklury (remdesivir) for COVID-19
Published: July 16, 2022 | Tags: Gilead, Veklury, remdesivir, COVID-19, Joint Procurement Agreement, EC, Pharma, COVID-19
Published: July 16, 2022 | Tags: Innovent, Mazdutide, IBI362, Type 2 Diabetes, Clinical Trials, P-II Study
Published: July 16, 2022 | Tags: Innovent, Ascentage, Olverembatinib, CML, Regulatory, NMPA, NDA, Priority Review Designation
Published: July 15, 2022 | Tags:Roche, Avista, AAV Gene Therapy Vectors, Ocular Diseases, Pharma
Published: July 15, 2022 | Tags: Daiichi Sankyo, AstraZeneca, Enhertu, trastuzumab deruxtecan, HER2 Positive Metastatic Breast Cancer, Regulatory, EU, Approval
Acadia Reports the NDA Submission of Trofinetide to the US FDA for the Treatment of Rett Syndrome
Published: July 15, 2022 | Tags: Acadia, Trofinetide, Rett Syndrome, NDA, Regulatory, P-III, Lavender study
Published: July 15, 2022 | Tags: Rhythm, NICE, Imcivree, setmelanotide, Obesity, Hunger, Regulatory, POMC, LEPR Deficiency
Incyte's Opzelura (ruxolitinib) Receives the US FDA's Approval for the Treatment of Vitiligo
Published: July 15, 2022 | Tags: Incyte, Opzelura, ruxolitinib, Vitiligo, Regulatory, US, FDA, Approval
Published: July 15, 2022 | Tags: Erasca, Eli Lilly, ERAS-601, Cetuximab, Cancer, Pharma, Supply Agreement
Zomedica Acquires Assisi’s Assets and Provide Drug-Free Solution for Treating Pain
Published: July 14, 2022 | Tags: Zomedica, Assisi, Assets, Acquires, Drug-Free Solution, Animal Health, Pain
Published: July 14, 2022 | Tags: PureTech, Akili, AKL-T01, Systemic Lupus Erythematosus, Clinical Trials, EVO Monitor, Lupus
AbbVie Reports Submission of MAA to EMA for Atogepant to Treat Migraine
Published: July 14, 2022 | Tags: Roche, Perjeta, pertuzumab, HER2-Positive Early Breast Cancer, Clinical Trial, P-III, APHINITY Study, ESMO, 2022
Published: July 14, 2022 | Tags: Roche, Perjeta, pertuzumab, HER2-Positive Early Breast Cancer, Clinical Trial, P-III, APHINITY Study, ESMO, 2022
SIGA Collaborated with KaliVir Immunotherapeutics to Supply Tpoxx for the Treatment of Smallpox
Published: July 14, 2022 | Tags: SIGA, KaliVir Immunotherapeutics, Tpoxx, tecovirimat, Smallpox, Pharma, Oncolytic Vaccinia Immunotherapy Platform
Published: July 14, 2022 | Tags: Calliditas, Kinpeygo, Primary Immunoglobulin A Nephropathy, Regulatory, EC Marketing Authorization
Related Post: PharmaShots Weekly Snapshots (July 11 – 15, 2022)
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.